Direct detection and quantification of abasic sites for in vivo studies of DNA damage and repair

Nuclear Medicine and Biology

Volumn 36, Issue 8, 2009, Pages 975-983

  Wang, Yanming ^a   Liu, Lili ^b   Wu, Chunying ^a   Bulgar, Alina ^b   Somoza, Eduardo ^a   Zhu, Wenxia ^a   Gerson, Stanton L ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Abasic sites; Apurinic apyrimidinic sites; DNA; PET imaging; TMZ; Tumor

Indexed keywords

CARBON 11; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; METHOXYAMINE C 11; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING KINETICS; BIOASSAY; CANCER CELL CULTURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG RETENTION; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; GLIOMA; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; TUMOR XENOGRAFT;

ANIMALS; BASE SEQUENCE; CARBON RADIOISOTOPES; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; FEMALE; GLIOMA; HYDROXYLAMINES; MELANOMA; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; RADIOPHARMACEUTICALS;

EID: 70350244389     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.07.007     Document Type: Article

References (34)

1. Neidle S., and Thurston D.E. Chemical approaches to the discovery and development of cancer therapies. Nat Rev Cancer 5 (2005) 285-296
2. Friedberg E.C. DNA damage and repair. Nature 421 (2003) 436-440
3. Stevens M.F., Hickman J.A., Langdon S.P., et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47 (1987) 5846-5852
4. Newlands E.S., Stevens M.F., Wedge S.R., Wheelhouse R.T., and Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23 (1997) 35-61
5. Taliansky-Aronov A., Bokstein F., Lavon I., and Siegal T. Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol 79 (2006) 153-157
6. Trudeau M.E., Crump M., Charpentier D., et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol 17 (2006) 952-956
7. Hegi M.E., Diserens A.C., Godard S., et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10 (2004) 1871-1874
8. Lanzetta G., Campanella C., Rozzi A., et al. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial. Anticancer Res 23 (2003) 5159-5164
9. Mason W.P., and Cairncross J.G. Drug insight: temozolomide as a treatment for malignant glioma-impact of a recent trial. Nat Clin Pract Neurol 1 (2005) 88-95
10. Liu L., and Gerson S.L. Targeted modulation of MGMT: clinical implications. Clin Cancer Res 12 (2006) 328-331
11. Gerson S.L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4 4 (2004) 296-307
12. Modrich P., and Lahue R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem 65 (1996) 101-133
13. Caporali S., Falcinelli S., Starace G., et al. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol 66 (2004) 478-491
14. David S.S., and Williams S.D. Chemistry of glycosylases and endonucleases involved in base-excision repair. Chem Rev 98 (1998) 1221-1262
15. Fromme J.C., and Verdine G.L. Base excision repair. Adv Protein Chem 69 (2004) 1-41
16. Barnes D.E., and Lindahl T. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet 38 (2004) 445-476
17. Lindahl T., and Wood R.D. Quality control by DNA repair. Science 286 (1999) 1897-1905
18. David S.S., O'Shea V.L., and Kundu S. Base-excision repair of oxidative DNA damage. Nature 447 (2007) 941-950
19. Trivedi R.N., Almeida K.H., Fornsaglio J.L., Schamus S., and Sobol R.W. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 65 (2005) 6394-6400
20. Kingma P.S., Corbett A.H., Burcham P.C., Marnett L.J., and Osheroff N. Abasic sites stimulate double-stranded DNA cleavage mediated by topoisomerase II. DNA lesions as endogenous topoisomerase II poisons. J Biol Chem 270 (1995) 21441-21444
21. Bigioni M., Zunino F., Tinelli S., Austin C.A., Willmore E., and Capranico G. Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity. Biochemistry 35 (1996) 153-159
22. Kingma P.S., and Osheroff N. Apurinic sites are position-specific topoisomerase II poisons. J Biol Chem 272 (1997) 1148-1155
23. Sabourin M., and Osheroff N. Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions. Nucleic Acids Res 28 (2000) 1947-1954
24. Rosa S., Fortini P., Karran P., Bignami M., and Dogliotti E. Processing in vitro of an abasic site reacted with methoxyamine: a new assay for the detection of abasic sites formed in vivo. Nucleic Acids Res 19 (1991) 5569-5574
25. Fortini P., Rosa S., Zijno A., Calcagnile A., Bignami M., and Dogliotti E. Methoxyamine modification of abasic sites protects CHO cells from the cytotoxic and mutagenic effects of oxygen alkylation. Carcinogenesis 13 (1992) 87-93
26. Taverna P., Liu L., Hwang H.S., Hanson A.J., Kinsella T.J., and Gerson S.L. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat Res 485 (2001) 269-281
27. Liu L., Yan L., Donze J.R., and Gerson S.L. Blockage of abasic site repair enhances antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts. Mol Cancer Ther 2 (2003) 1061-1066
28. Liuzzi M., and Talpaert-Borle M. A new approach to the study of the base-excision repair pathway using methoxyamine. J Biol Chem 260 (1985) 5252-5258
29. Liu L., and Gerson S.L. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr Opin Investig Drugs 5 (2004) 623-627
30. Liu L., Taverna P., Whitacre C.M., Chatterjee S., and Gerson S.L. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res 5 (1999) 2908-2917
31. Nakamura J., Walker V.E., Upton P.B., Chiang S.Y., Kow Y.W., and Swenberg J.A. Highly sensitive apurinic/apyrimidinic site assay can detect spontaneous and chemically induced depurination under physiological conditions. Cancer Res 58 (1998) 222-225
32. Atamna H., Cheung I., and Ames B.N. A method for detecting abasic sites in living cells: age-dependent changes in base excision repair. PNAS 97 (2000) 686-691
33. Jaruga P., and Dizdaroglu M. Repair of products of oxidative DNA base damage in human cells. Nucleic Acids Res 24 8 (1996) 1389-1394
34. Liu L., Allay E., et al. Rapid repair of O6-methylguanine-DNA adducts protects transgenic mice from N-methylnitrosourea-induced thymic lymphomas. Cancer Res 54 17 (1994) 4648-4652